REGENXBIO Inc. (NASDAQ:RGNX) Stock Position Raised by Stifel Financial Corp

Stifel Financial Corp grew its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 26.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 188,844 shares of the biotechnology company's stock after purchasing an additional 39,564 shares during the period. Stifel Financial Corp owned 0.38% of REGENXBIO worth $1,460,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Voss Capital LP bought a new stake in REGENXBIO in the fourth quarter valued at $2,573,000. Tower Research Capital LLC TRC increased its holdings in shares of REGENXBIO by 442.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 10,714 shares during the period. Dimensional Fund Advisors LP lifted its position in REGENXBIO by 1.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock valued at $9,054,000 after purchasing an additional 21,234 shares during the last quarter. Jump Financial LLC lifted its position in REGENXBIO by 144.9% in the 4th quarter. Jump Financial LLC now owns 192,708 shares of the biotechnology company's stock valued at $1,490,000 after purchasing an additional 114,005 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in REGENXBIO during the 4th quarter valued at about $681,000. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Stock Up 0.5%

NASDAQ RGNX traded up $0.04 on Tuesday, reaching $8.01. 815,446 shares of the stock traded hands, compared to its average volume of 850,261. The firm's fifty day simple moving average is $7.36 and its 200 day simple moving average is $7.99. The company has a market cap of $401.44 million, a price-to-earnings ratio of -1.59 and a beta of 1.11. REGENXBIO Inc. has a 12 month low of $5.04 and a 12 month high of $16.85.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, equities research analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGNX has been the topic of several analyst reports. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research note on Tuesday, March 18th. The Goldman Sachs Group lowered their target price on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. HC Wainwright cut their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 target price on the stock. Finally, Morgan Stanley lifted their target price on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.